Cogent Biosciences, Inc. announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations.

A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST). Mr. Pinnow has 25 years of global and U.S. commercial experience, including multiple product launches as well as new product planning, sales and acquisitions. Mr. Pinnow joins Cogent from Pfizer, where he has held increasing roles of responsibility, including President and Managing Director of Pfizer Canada and most recently as Global Franchise Lead, Genitourinary and Breast Cancer Business where he led a global commercial team accountable for the growth of a $5B innovative cancer portfolio in prostate, kidney, bladder and breast therapies.

Prior to Pfizer, he held several leadership roles with Hospira and founded the company?s commercial development organization. Mr. Pinnow began his pharmaceutical career as a scientist at Abbott Laboratories. Mr. Pinnow holds a Bachelor of Arts degree in Biology from St.

Olaf College in Minnesota and a Master of Business Administration from the University of Chicago, Booth School of Management as well as a Master of Sciences degree in Microbiology from Iowa State University.